

DocumentUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 6-KREPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934Date of report: January 27, 2025Commission File Number: 001-39084Innate Pharma S.A.(Translation of registrant's name into English)Innate Pharma S.A.117 Avenue de Luminyâ€"BP 3019113009 Marseille, France+ 33 (0) 4 30 30 30(Address of principal executive office)Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]  Form 40-F [ ]INCORPORATION BY REFERENCETHis Report on Form 6-K and Exhibit 99.1 to this Report on Form 6-K (excluding the quotation from Dr Shiraj Sen, Medical Oncologist and Phase 1 Investigator, Director of Clinical Research, NEXT Oncology-Dallas, and the quotation from Dr Sonia Quarantino, EVP, Chief Medical Officer at Innate Pharma) shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-276164) and registration statement on Form S-8 (File No. 333-282031) of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.EXHIBIT INDEXExhibit A A A Description99.1 A A A Press Release dated January 27, 2025SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.INNATE PHARMA S.A.Date: January 27, 2025A A A By: A A A /s/ JONATHAN DICKINSON A A A Name: A A A Jonathan DickinsonTitle: A A A Chairman of the Executive Board and Chief Executive OfficerDocumentEXHIBIT 99.1Innate Pharma Announces First Patient Dosed In Phase 1 Study Of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 In Selected Advanced Solid TumorsMarseille, France, January 27, 2025, 7:00 A.M. CETâ€¢IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (â€œInnateâ€ or the â€œCompanyâ€) today announced the first patient was dosed in its Phase 1 study (NCT06781983), investigating the safety and tolerability of IPH4502, an innovative Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors known to express Nectin-4IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, including urothelial carcinoma (UC), breast cancer, non-small cell lung cancer or gastro-intestinal cancer. IPH4502 targets tumors with a wide range of Nectin-4 expression, supporting its development beyond UC. IPH4502 differentiated topoisomerase I inhibitor payload supports its potential in patients with tumors resistant to MMAE-ADC. The Phase 1, open-label, multi-center study, includes a Part 1 Dose Escalation and a Part 2 Dose Optimization, and will assess the safety, tolerability, and preliminary efficacy of IPH4502 as a single agent in advanced solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. The study plans to enroll approximately 105 patients.â€œWe are thrilled to initiate the Phase 1 study with IPH4502, a promising therapy for patients with advanced solid tumors known to express Nectin-4,â€ said Dr Shiraj Sen, Medical Oncologist and Phase 1 Investigator, Director of Clinical Research, NEXT Oncology-Dallas. â€œIPH4502 is uniquely designed to target tumors with both high and low expression of Nectin-4, offering hope for improved outcomes in a population where effective treatment options are limited, and relapses occur frequently. This study represents an important step forward in advancing innovative care for these patients.â€ â€œThe initiation of this Phase 1 trial represents a significant milestone for Innate Pharma as our clinical stage pipeline now includes targeted ADCs. We are optimistic about the potential of IPH4502 to address unmet needs in the treatment of advanced solid tumors, with a well differentiated Nectin-4 targeting and the promise of ADC technology to provide a new therapeutic option for patients,â€ added Dr Sonia Quarantino, Chief Medical Officer at Innate Pharma. More information about the trial can be found on clinicaltrials.gov.About IPH4502IPH4502 is a novel topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4. It is currently investigated in a Phase 1 trial in advanced solid tumors expressing Nectin-4.Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, esophageal, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues. In non-clinical models, IPH45 is well tolerated and shows anti-tumor activity in vitro and in vivo. About Innate Pharma:Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKETâ® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).Innateâ€™s portfolio includes several ANKETâ® drug candidates to address multiple tumor types as well as IPH4502 a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.Learn more about Innate Pharma at [www.innate-pharma.com](http://www.innate-pharma.com) and follow us on LinkedIn and X.Information about Innate Pharma shares:ISIN codeA : FR0010331421Ticker codeA : Euronext: IPH Nasdaq: IPHALEI A : 9695002Y8420ZB8HJE29Disclaimer on forward-looking information and risk factors: This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including â€œanticipate,â€ â€œbelieve,â€ â€œcan,â€ â€œcould,â€ â€œestimate,â€ â€œexpect,â€ â€œmay,â€ â€œmight,â€ â€œpotential,â€ â€œexpectâ€ â€œshould,â€ â€œwill,â€ or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Companyâ€™s reliance on third parties to manufacture its product candidates, the Companyâ€™s commercialization efforts and the Companyâ€™s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (â€œFacteurs de Risqueâ€) section of the Universal Registration Document filed with the French Financial Markets Authority (â€œAMFâ€), which is available on the AMF website <http://www.amf-france.org> or on Innate Pharmaâ€™s website, and public filings and reports filed with the U.S. Securities and Exchange Commission

(â€œSECâ€), including the Companyâ€™s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Companyâ€™s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. For additional information, please contact: [Investors@Innate-Pharma.fr](mailto:Investors@Innate-Pharma.fr) Tel.: +33 (0)4 84 90 32 88 [Henry.Wheeler@innate-pharma.fr](mailto:Henry.Wheeler@innate-pharma.fr) Media RelationsNewCapArthur RouilleTel. : +33 (0)1 44 71 00 15 [innate@newcap.eu](mailto:innate@newcap.eu)